Logo Image
News|Articles|September 23, 2026

Linvoseltamab Shows 100% Response Rate in Smoldering Myeloma, Raising Early-Intervention Question

Listen
0:00 / 0:00

Key Takeaways

  • Linvoseltamab moved from FDA-approved ≥4L RRMM into HR-SMM, challenging the traditional “treat at symptomatic progression” paradigm with deep early responses by IMWG criteria.
  • Efficacy signals were striking: 100% ORR, 97% ≥VGPR, 69% CR, with ongoing deepening responses and no progression to active myeloma at 8.6 months.
SHOW MORE

Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.

Updated results from the phase 2 LINKER-SMM1 trial show that linvoseltamab monotherapy produced a 100% objective response rate in patients with high-risk smoldering multiple myeloma (HR-SMM), with no progression to active disease at a median follow-up of 8.6 months.1

Presented at the 23rd International Myeloma Society Annual Meeting, the data extend the drug's use well upstream of its current FDA-approved indication and reopen a long-running debate in the field over how early bispecific therapy should be initiated.

From A Fourth-Line Bispecific To A Precursor-Disease Candidate

Linvoseltamab (Lynozyfic; Regeneron) received FDA accelerated approval in July 2025 as a fully human BCMA×CD3 bispecific antibody for adult patients with RRMM who have received at least 4 prior lines of therapy. The decision was based on response data from the phase 1/2 LINKER-MM1 trial (NCT03761108), in which 80 patients achieved a 70% overall response rate and 45% complete response rate.2,3 That approval placed linvoseltamab squarely in the heavily pretreated, triple-class exposed population alongside teclistamab and elranatamab.1

LINKER-SMM1 tests something categorically different: using the same mechanism to intercept disease before it meets the diagnostic criteria for active multiple myeloma at all. In this update, 32 evaluable patients with HR-SMM who completed at least 1 treatment cycle achieved a 100% investigator-assessed overall response rate per International Myeloma Working Group (IMWG) criteria, with 97% reaching very good partial response (VGPR) or better and 69% reaching complete response (CR).1

Responses continued to deepen over time, and among MRD-evaluable patients with VGPR or better, 100% reached MRD negativity at the 10⁻⁵ threshold and 10⁻⁶ sensitivity. No patient progressed to active myeloma during the observation period.1

Tolerability Data Support Outpatient Feasibility

The safety profile leaned favorable for a bispecific used in a non-malignant, precursor-disease population. Infections occurred in 92% of patients, but grade 3 events were limited to 19% and resolved with routine clinical care; no immune cell-associated neurotoxicity syndrome was reported, and cytokine release syndrome was managed with tocilizumab when it occurred.1

All patients received standard infection-prophylaxis supportive care, including IVIG replacement and pneumocystis pneumonia prophylaxis—a reminder that even in an ostensibly lower-risk population, the supportive-care bundle around bispecific therapy does not change.1

The Access and Formulary Question This Raises

For pharmacists, LINKER-SMM1 is less an immediate practice changer than a preview of a coverage question headed toward formularies within the next several years. Current payer coverage criteria for BCMA-directed bispecifics are built almost entirely around the concept of "active myeloma," requiring at least 4 prior lines of therapy—criteria that simply do not contemplate treating smoldering, asymptomatic disease.

If a phase 3 registrational study—which is already underway, per trial investigators—confirms this early-intervention signal, prior authorization pathways, site-of-care determinations, and even the clinical definition of "when treatment starts" in myeloma could shift meaningfully.

The Mayo Clinic-led 20/2/20 risk stratification model for smoldering myeloma has already reshaped how oncologists identify the highest-risk patients most likely to benefit from such intervention, making the population that LINKER-SMM1 targeted a well-defined, actionable one rather than a theoretical subgroup.4

Given how quickly MRD-driven, bispecific-based strategies have already moved from investigational to guideline-preferred status in relapsed disease, pharmacists working in myeloma-focused health systems should not assume this early-intervention question stays academic for long.

REFERENCES
1. Rodríguez-Otero P, Amer Salas N, Clavero ME, et al. Updated safety and efficacy results for linvoseltamab (LINVO) in patients with high-risk smoldering multiple myeloma (HR-SMM): phase 2 LINKER-SMM1 trial. Presented at: 23rd International Myeloma Society Annual Meeting; September 23-26, 2026; Glasgow, Scotland.
2. FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma. News release FDA. July 2, 2025. Accessed September 23, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-linvoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma
3. Lynozyfic (linvoseltamab-gcpt) [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals Inc; 2025. Accessed September 23, 2026. www.regeneron.com/downloads/lynozyfic_fpi.pdf
4. Mateos MV, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102. doi:10.1038/s41408-020-00366-3

Related to this article

View more